Digestive Diseases and Sciences, a renowned medical journal in the gastroenterology and hepatology fields, published the results of the Irritable Bowel Syndrome Reduction Evaluation and Safety Trial study.
Here are five notes:
1. The study titled, "A Novel Delivery System of Peppermint Oil is an Effective Therapy For Irritable Bowel Syndrome," is presently available for the public through the open access on the home page of the Digestive Disease and Sciences website.
2. The study was four weeks and consisted of a randomized, placebo-controlled, double-bind clinical trial at multiple centers throughout the United States.
3. Of the participants, 72 patients were randomized to IBgard or placebo and were administered three doses daily for four weeks.
4. The findings revealed the IBgard treatment indicated a 20 percent reduction in the Total IBS Symptom Score from baseline in as early as 24 hours. This figure was a statistically important reduction compared to the placebo.
5. Additionally, the IBgard treatment had a 40 percent reduction in the TISS from baseline at four weeks.
More GI/endoscopy news:
GI physician leader to know: Dr. Francis Chan of Gastroenterology Center of Connecticut
5 most read GI/endoscopy stories – Week of Sept. 28 to Oct. 2
Victoria Hospital to polish physicians' expertise in endoscopy, colonoscopy: 4 key points